Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) EPS (Weighted Average and Diluted) (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.38 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 152.78% to -$0.38 in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.89, a 1826.67% decrease, with the full-year FY2025 number at -$1.79, up 55.91% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.38 for Q4 2025 at Outlook Therapeutics, down from -$0.19 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.72 in Q4 2024 to a low of -$1.77 in Q1 2025.